PH 46A

Drug Profile

PH 46A

Alternative Names: PH46A

Latest Information Update: 25 Sep 2014

Price : $50

At a glance

  • Originator Trino Therapeutics
  • Class Anti-inflammatories; Benzoates; Indans; Muscle relaxants; Small molecules; Stem cell therapies
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ulcerative colitis

Most Recent Events

  • 31 Aug 2014 Trino Therapeutics completes a phase I trial in Ulcerative colitis (In volunteers) in United Kingdom (ISRCTN90725219)
  • 07 Feb 2014 Phase-I clinical trials in Ulcerative colitis (in volunteers) in United Kingdom (PO)
  • 04 Jun 2012 Pharmacodynamics data from a preclinical trial in Ulcerative colitis released by Trino Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top